相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tamoxifen pharmacogenetics ofCYP2D6, CYP2C19, andSULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial.
MP Goetz et al.
CANCER RESEARCH (2010)
Pharmacogenetic Pathway Analysis of Docetaxel Elimination
S. D. Baker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues
David Holzman
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
Anne M. Schultheis et al.
CLINICAL CANCER RESEARCH (2008)
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy
Sharon E. Johnatty et al.
CLINICAL CANCER RESEARCH (2008)
Pharmacogenetics in Breast Cancer Therapy
Sing-Huang Tan et al.
CLINICAL CANCER RESEARCH (2008)
Anti-VEGF therapy: the search for clinical biomarkers
Raffaele Longo et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2008)
Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer
Chaitanya R. Acharya et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
Tristan M. Sissung et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients
S. Y. Hor et al.
PHARMACOGENOMICS JOURNAL (2008)
Association of polymorphisms of angiogenesis genes with breast cancer
Bryan P. Schneider et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response
M. P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer
Sharon Marsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
S. Marsh et al.
PHARMACOGENOMICS JOURNAL (2007)
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer
Hyeong-Seok Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
Lionel D. Lewis et al.
CLINICAL CANCER RESEARCH (2007)
The prognostic role of a gene signature from tumorigenic breast-cancer cells.
Rui Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Pia Wegman et al.
BREAST CANCER RESEARCH (2007)
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel
Tessa M. Bosch et al.
CLINICAL CANCER RESEARCH (2006)
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells
Young Chai Lim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetics and toxicity of docetaxel:: Role of CYP3A, MDR1, and GST polymorphisms
A Tran et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue:: G2677T/A correlates with response to paclitaxel chemotherapy
H Gréen et al.
CLINICAL CANCER RESEARCH (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical pharmalcokinetics of docetaxel - Recent developments
SD Baker et al.
CLINICAL PHARMACOKINETICS (2006)
Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort
EJ Jacobs et al.
BREAST CANCER RESEARCH (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Human aromatase: Gene resequencing and functional genomics
CX Ma et al.
CANCER RESEARCH (2005)
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid
MT Huisman et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
NF Smith et al.
CANCER BIOLOGY & THERAPY (2005)
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
SA Nowell et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1
M Nakajima et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis
QR Jin et al.
CLINICAL CANCER RESEARCH (2005)
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol
N Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prediction of docetaxel response in human breast cancer by gene expression profiling
K Iwao-Koizumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
P Wegman et al.
BREAST CANCER RESEARCH (2005)
Dexamethasone as a probe for docetaxel clearance
F Puisset et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk
P Krippl et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy
A Sparreboom et al.
DRUG RESISTANCE UPDATES (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations
RHJ Mathijssen et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
Pharmacogenetics and adverse drug reactions
UA Meyer
LANCET (2000)
Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol
N Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
DS Streetman et al.
PHARMACOGENETICS (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
